News

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive ...
Investors in Landmark Bancorp (NASDAQ:LARK) have seen decent returns of 36% over the past year
It might be of some concern to shareholders to see the Landmark Bancorp, Inc. ( NASDAQ:LARK ) share price down 18% ...